Durable Response to Vemurafenib and Cobimetinib for the Treatment of BRAF-Mutated Metastatic Melanoma in Routine Clinical Practice

5-Year Outcomes with Cobimetinib plus Vemurafenib in BRAFV600 Mutation–Positive Advanced Melanoma: Extended Follow-up of the coBRIM Study

(2021) Paolo A. Ascierto et al.   CLINICAL CANCER RESEARCH

Targeted agents or immuno-oncology therapies as first-line therapy for BRAF-mutated metastatic melanoma: a real-world study

(2019) Jason J Luke et al.   Future Oncology

Real-world treatment patterns and clinical outcomes among patients with advanced melanoma

(2019) C. Lance Cowey et al.   MEDICINE

Management of V600E and V600K BRAF-Mutant Melanoma

(2019) Alexandra M. Haugh et al.   CURRENT TREATMENT OPTIONS IN ONCOLOGY

Real‐world survival of patients with advanced BRAF V600 mutated melanoma treated with front‐line BRAF/MEK inhibitors, anti‐PD‐1 antibodies, or nivolumab/ipilimumab

(2019) Justin C. Moser et al.   Cancer Medicine

A systematic literature review and network meta-analysis of effectiveness and safety outcomes in advanced melanoma

(2019) Margreet G. Franken et al.   EUROPEAN JOURNAL OF CANCER

Health-related quality of life impact of cobimetinib in combination with vemurafenib in patients with advanced or metastatic BRAFV600 mutation–positive melanoma

(2018) Brigitte Dréno et al.   BRITISH JOURNAL OF CANCER

The Hospital Anxiety and Depression Scale is a screening measure of general distress

(2018) A.G. Affleck et al.   BRITISH JOURNAL OF DERMATOLOGY

Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis

(2018) Jennifer L McQuade et al.   LANCET ONCOLOGY

Personalized Medicine in Malignant Melanoma: Towards Patient Tailored Treatment

(2018) Hildur Helgadottir et al.   Frontiers in Oncology

Clinical experience with combination BRAF/MEK inhibitors for melanoma with brain metastases

(2018) Joshua Z. Drago et al.   MELANOMA RESEARCH

Association between Body Mass Index, C-Reactive Protein Levels, and Melanoma Patient Outcomes

(2017) Shenying Fang et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Molecular testing for BRAF mutations to inform melanoma treatment decisions: a move toward precision medicine

(2017) Liang Cheng et al.   MODERN PATHOLOGY

M08Monoinstitutional experience of vemurafenib and cobimetinib for BRAF mutated metastatic melanoma

(2016) L. Di Guardo et al.   ANNALS OF ONCOLOGY

BRAF-V600E expression in primary nodular melanoma is associated with aggressive tumour features and reduced survival

(2016) Emilia Hugdahl et al.   BRITISH JOURNAL OF CANCER

The Obesity Paradox in Cancer: a Review

(2016) Hannah Lennon et al.   Current Oncology Reports

Duration of Adulthood Overweight, Obesity, and Cancer Risk in the Women’s Health Initiative: A Longitudinal Study from the United States

(2016) Melina Arnold et al.   PLOS MEDICINE

Targeted Therapies in Melanoma: Translational Research at Its Finest

(2015) Allen W. Ho et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Combination therapy with BRAF and MEK inhibitors for melanoma: latest evidence and place in therapy

(2015) Zeynep Eroglu et al.   Therapeutic Advances in Medical Oncology

Prognostic and Clinicopathologic Associations of OncogenicBRAFin Metastatic Melanoma

(2011) Georgina V. Long et al.   JOURNAL OF CLINICAL ONCOLOGY

Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation

(2011) Paul B. Chapman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Final Version of 2009 AJCC Melanoma Staging and Classification

(2009) Charles M. Balch et al.   JOURNAL OF CLINICAL ONCOLOGY